1
|
Liu XT, Dong XL, Zhang Y, Fang P, Shi HY, Ming ZJ. Diagnostic value and safety of medical thoracoscopy for pleural effusion of different causes. World J Clin Cases 2022; 10:3088-3100. [PMID: 35647131 PMCID: PMC9082710 DOI: 10.12998/wjcc.v10.i10.3088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2021] [Revised: 01/31/2022] [Accepted: 02/23/2022] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Pleural effusions occur for various reasons, and their diagnosis remains challenging despite the availability of different diagnostic modalities. Medical thoracoscopy (MT) can be used for both diagnostic and therapeutic purposes, especially in patients with undiagnosed pleural effusion.
AIM To assess the diagnostic efficacy and safety of MT in patients with pleural effusion of different causes.
METHODS Between January 1, 2012 and April 30, 2021, patients with pleural effusion underwent MT in the Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University (Shaanxi, China). According to the discharge diagnosis, patients were divided into malignant pleural effusion (MPE), tuberculous pleural effusion (TBPE), and inflammatory pleural effusion (IPE) groups. General information, and tuberculosis- and effusion-related indices of the three groups were analyzed. The diagnostic yield, diagnostic accuracy, performance under thoracoscopy, and complications of patients were compared among the three groups. Then, the significant predictive factors for diagnosis between the MPE and TBPE groups were analyzed.
RESULTS Of the 106 patients enrolled in this 10-year study, 67 were male and 39 female, with mean age of 57.1 ± 14.184 years. Among the 74 thoracoscopy-confirmed patients, 41 (38.7%) had MPE, 21 had (19.8%) TBPE, and 32 (30.2%) were undiagnosed. Overall diagnostic yield of MT was 69.8% (MPE: 75.9%, TBPE: 48.8%, and IPE: 75.0%, with diagnostic accuracies of 100%, 87.5%, and 75.0%, respectively). Under thoracoscopy, single or multiple pleural nodules were observed in 81.1% and pleural adhesions in 34.0% with pleural effusions. The most common complication was chest pain (41.5%), followed by chest tightness (11.3%) and fever (10.4%). Multivariate logistic regression analyses showed effusion appearance [odds ratio (OR): 0.001, 95%CI: 0.000-0.204; P = 0.010] and carcinoembryonic antigen (OR: 0.243, 95%CI: 0.081-0.728; P = 0.011) as significant for differentiating MPE and TBPE, with area under the receiver operating characteristic curve of 0.977 (95%CI: 0.953-1.000; P < 0.001).
CONCLUSION MT is an effective, safe, and minimally invasive procedure with high diagnostic yield for pleural effusion of different causes.
Collapse
Affiliation(s)
- Xiao-Ting Liu
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China
| | - Xi-Lin Dong
- Department of Respiratory, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China
| | - Yu Zhang
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China
| | - Ping Fang
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China
| | - Hong-Yang Shi
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China
| | - Zong-Juan Ming
- Department of Respiratory Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, Shaanxi Province, China
| |
Collapse
|
2
|
Cao SG, Ming ZJ, Zhang YP, Yang SY. Sex-determining region of Y chromosome-related high-mobility-group box 2 in malignant tumors: current opinions and anticancer therapy. Chin Med J (Engl) 2015; 128:384-9. [PMID: 25635436 PMCID: PMC4837871 DOI: 10.4103/0366-6999.150112] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
Objective: To gain insight into the mechanism by which sex-determining region of Y chromosome (SRY)-related high-mobility-group box 2 (SOX2) involved in carcinogenesis and cancer stem cells (CSCs). Data Sources: The data used in this review were mainly published in English from 2000 to present obtained from PubMed. The search terms were “SOX2”, “cancer”, “tumor” or “CSCs”. Study Selection: Articles studying the mitochondria-related pathologic mechanism and treatment of glaucoma were selected and reviewed. Results: SOX2, a transcription factor that is the key in maintaining pluripotent properties of stem cells, is a member of SRY-related high-mobility group domain proteins. SOX2 participates in many biological processes, such as modulation of cell proliferation, regulation of cell death signaling, cell apoptosis, and most importantly, tumor formation and development. Although SOX2 has been implicated in the biology of various tumors and CSCs, the findings are highly controversial, and information regarding the underlying mechanism remains limited. Moreover, the mechanism by which SOX2 involved in carcinogenesis and tumor progression is rather unclear yet. Conclusions: Here, we review the important biological functions of SOX2 in different tumors and CSCs, and the function of SOX2 signaling in the pathobiology of neoplasia, such as Wnt/β-catenin signaling pathway, Hippo signaling pathway, Survivin signaling pathway, PI3K/Akt signaling pathway, and so on. Targeting towards SOX2 may be an effective therapeutic strategy for cancer therapy.
Collapse
Affiliation(s)
| | | | | | - Shuan-Ying Yang
- Department of Respiratory Medicine, Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, Shaanxi 710004, China
| |
Collapse
|
3
|
Zhang Y, Yang WQ, Zhu H, Qian YY, Zhou L, Ren YJ, Ren XC, Zhang L, Liu XP, Liu CG, Ming ZJ, Li B, Chen B, Wang JR, Liu YB, Yang JM. Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin. Biochem Pharmacol 2013; 87:562-70. [PMID: 24345332 DOI: 10.1016/j.bcp.2013.12.004] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Revised: 11/29/2013] [Accepted: 12/02/2013] [Indexed: 12/11/2022]
Abstract
miR-30d has been observed to be significantly down-regulated in human anaplastic thyroid carcinoma (ATC), and is believed to be an important event in thyroid cell transformation. In this study, we found that miR-30d has a critical role in modulating sensitivity of ATC cells to cisplatin, a commonly used chemotherapeutic drug for treatment of this neoplasm. Using a mimic of miR-30d, we demonstrated that miR-30d could negatively regulate the expression of beclin 1, a key autophagy gene, leading to suppression of the cisplatin-activated autophagic response that protects ATC cells from apoptosis. A reporter gene assay demonstrated that the binding sequences of miR-30d in the beclin 1-3' UTR was the region required for the inhibition of beclin 1 expression by this miRNA. We further showed that inhibition of the beclin 1-mediated autophagy by the miR-30d mimic sensitized ATC cells to cisplatin both in vitro (cell culture) and in vivo (animal xenograft model). These results suggest that dysregulation of miR-30d in ATC cells is responsible for the insensitivity to cisplatin by promoting autophagic survival. Thus, miR-30d may be exploited as a potential target for therapeutic intervention in the treatment of ATC.
Collapse
Affiliation(s)
- Y Zhang
- Department of Pharmacology, College of Pharmaceutical Sciences, Hematology Center of Cyrus Tang Medical Institute, Affiliated Changshu Hospital, Soochow University, Suzhou, Jiangsu Province, China.
| | - W Q Yang
- Department of Pharmacology, College of Pharmaceutical Sciences, Hematology Center of Cyrus Tang Medical Institute, Affiliated Changshu Hospital, Soochow University, Suzhou, Jiangsu Province, China
| | - H Zhu
- Department of Surgery, School of Medicine, Ohio State University, USA
| | - Y Y Qian
- Department of Pharmacology, College of Pharmaceutical Sciences, Hematology Center of Cyrus Tang Medical Institute, Affiliated Changshu Hospital, Soochow University, Suzhou, Jiangsu Province, China
| | - L Zhou
- Department of Pharmacology, College of Pharmaceutical Sciences, Hematology Center of Cyrus Tang Medical Institute, Affiliated Changshu Hospital, Soochow University, Suzhou, Jiangsu Province, China
| | - Y J Ren
- Department of Pharmacology, College of Pharmaceutical Sciences, Hematology Center of Cyrus Tang Medical Institute, Affiliated Changshu Hospital, Soochow University, Suzhou, Jiangsu Province, China
| | - X C Ren
- Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, PA, USA
| | - L Zhang
- Department of Pharmacology, College of Pharmaceutical Sciences, Hematology Center of Cyrus Tang Medical Institute, Affiliated Changshu Hospital, Soochow University, Suzhou, Jiangsu Province, China
| | - X P Liu
- Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA
| | - C G Liu
- Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX, USA
| | - Z J Ming
- Department of Pharmacology, College of Pharmaceutical Sciences, Hematology Center of Cyrus Tang Medical Institute, Affiliated Changshu Hospital, Soochow University, Suzhou, Jiangsu Province, China
| | - B Li
- Department of Surgery, School of Medicine, Ohio State University, USA
| | - B Chen
- Department of Pharmacology, College of Pharmaceutical Sciences, Hematology Center of Cyrus Tang Medical Institute, Affiliated Changshu Hospital, Soochow University, Suzhou, Jiangsu Province, China
| | - J R Wang
- Department of Pharmacology, College of Pharmaceutical Sciences, Hematology Center of Cyrus Tang Medical Institute, Affiliated Changshu Hospital, Soochow University, Suzhou, Jiangsu Province, China
| | - Y B Liu
- Department of General Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China
| | - J M Yang
- Department of Pharmacology, College of Pharmaceutical Sciences, Hematology Center of Cyrus Tang Medical Institute, Affiliated Changshu Hospital, Soochow University, Suzhou, Jiangsu Province, China; Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, PA, USA.
| |
Collapse
|
4
|
Zhang XDE, Yang SY, Li W, Ming ZJ, Hou YL, Niu ZQ, Zhang YP. Adult Henoch-Schönlein purpura associated with small cell lung cancer: A case report and review of the literature. Oncol Lett 2013; 5:1927-1930. [PMID: 23833668 PMCID: PMC3701082 DOI: 10.3892/ol.2013.1274] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2012] [Accepted: 03/14/2013] [Indexed: 11/29/2022] Open
Abstract
The present study reports the case of a 53-year-old male who had been suffering from coughing and the presence of a blood-streaked sputum for >1 month. Chest computed tomography (CT) and a bronchoscopic brush smear were performed. The patient was subsequently diagnosed with small cell lung cancer (limited stage). The patient developed polyarthritis, abdominal pain, diarrhea and a purpuric rash at 14 days post thoracotomy surgery for lung cancer. Henoch-Schönlein purpura (HSP) was diagnosed based on the clinical symptoms. The patient received chemotherapy with steroid therapy, which resulted in complete remission of the HSP.
Collapse
Affiliation(s)
- Xue-DE Zhang
- Department of Respiratory Medicine, The Second Affliated Hospital, Medical College of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China
| | | | | | | | | | | | | |
Collapse
|
5
|
Ming ZJ, Hu Y, Qiu YH, Cao L, Zhang XG. Synergistic effects of beta-aescin and 5-fluorouracil in human hepatocellular carcinoma SMMC-7721 cells. Phytomedicine 2010; 17:575-580. [PMID: 20106644 DOI: 10.1016/j.phymed.2009.12.009] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/03/2009] [Revised: 10/23/2009] [Accepted: 12/14/2009] [Indexed: 05/28/2023]
Abstract
The effects and mechanisms of action of beta-aescin and 5-fluorouracil (5-FU), alone and in combination, were studied in human hepatocellular carcinoma SMMC-7721 cells. Growth inhibition, cell cycle distribution, apoptosis, Bcl-2 expression and caspase activity were assessed. The Isobole-method/interaction-index analysis was applied to evaluate the synergy, additivity or antagonism of these agents. The results indicate that mixtures of beta-aescin and 5-FU showed a synergistic effect on the 50% inhibitory effect when their ratio was 4:1 when compared with either agent alone. The mechanism of action could be through the synergistic arrest of the cell cycle, induction of apoptosis, activation of caspases-3, 8 and 9, and down-regulation Bcl-2 expression. The results suggest that mixtures of these two agents had a synergistic inhibitory effect on SMMC-7721 cells, an observation which might be useful for the further development of anti-cancer drugs.
Collapse
Affiliation(s)
- Z J Ming
- School of Pharmacy, College of Medicine, Soochow University, Suzhou 215123, PR China.
| | | | | | | | | |
Collapse
|